{{Rsnum
|rsid=7144886
|Chromosome=14
|position=69364320
|Orientation=plus
|GMAF=0.1492
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 79.6 | 18.6 | 1.8
| HCB | 74.5 | 21.9 | 3.6
| JPT | 68.1 | 26.5 | 5.3
| YRI | 72.1 | 25.2 | 2.7
| ASW | 59.6 | 40.4 | 0.0
| CHB | 74.5 | 21.9 | 3.6
| CHD | 70.6 | 27.5 | 1.8
| GIH | 75.2 | 23.8 | 1.0
| LWK | 64.5 | 30.0 | 5.5
| MEX | 91.4 | 8.6 | 0.0
| MKK | 76.9 | 21.8 | 1.3
| TSI | 74.5 | 24.5 | 1.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7144886
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109403
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7144886
|overall_frequency_n=15
|overall_frequency_d=128
|overall_frequency=0.117188
|n_genomes=11
|n_genomes_annotated=0
|n_haplomes=11
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}